AVI-205

AVI-205 is a preclinical **COVID-19 vaccine candidate** developed by **AbVision** using the company's **ImmunoBuster-II Active Targeting Vaccine Platform**. Based on company disclosures, the vaccine is designed to **actively target immune cells after injection** rather than rely solely on passive diffusion, with the aim of accelerating and amplifying vaccine-induced immunity. In mouse preclinical studies, AVI-205 induced **anti-SARS-CoV-2 spike S1 IgG antibodies** and serum from vaccinated animals inhibited **SARS-CoV-2 S1 binding to human ACE2**, consistent with a neutralizing antibody mechanism directed against the viral spike receptor-binding interaction. Publicly available information does not clearly disclose the exact antigen construct, adjuvant composition, dosage form, or clinical-stage details beyond its **preclinical** status and availability for out-licensing.

Other names

Active Targeting COVID-19 Vaccine